Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Author:
Funder
Samsung Bioepis Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Link
http://link.springer.com/content/pdf/10.1007/s40259-019-00381-2.pdf
Reference47 articles.
1. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269–80. https://doi.org/10.1038/ncponc0509 .
2. Nida I, Naveed I. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. https://doi.org/10.1155/2014/852748 .
3. Tarik R, Targeting RTK. Signaling pathways in cancer. Cancers (Basel). 2015;7(3):1758–84. https://doi.org/10.3390/cancers7030860 .
4. Ping W, Zhixiang W. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52. https://doi.org/10.3390/cancers9050052 .
5. Del Mastro L, Lambertini M, Bighin C, Levaggi A, D’Alonzo A, Giraudi S, et al. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Rev Anticancer Ther. 2012;12(11):1391–405. https://doi.org/10.1586/era.12.107 .
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study;Oncology;2023-10-27
2. Flow cytometry: A powerful analytical technique for characterizing the biological function of biotherapeutics and biosimilars.;Journal of Pharmaceutical and Biomedical Analysis;2023-10
3. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes;Analytical and Bioanalytical Chemistry;2023-05-10
4. Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer;Biomedicines;2022-08-21
5. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects;BioDrugs;2022-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3